G.d. Searle & Company

Pharmacia Corporation

Bipinchandra N Desai

Mark Andrew Russell

Michael John Clare

Alan Frank Gasiecki

Thomas Dale Penning

Barbara B Chen

Nizal S Chandrakumar

Thomas Edward Rogers

Julie M Miyashiro

Robert J Chorvat

Stevan Wakefield Djuric

Richard A Haack

Chi-Dean Liang

Stephen Hermann Docter

Richard A Mueller

Balekudru Devadas

Ish K Khanna

Joseph Gerace Rico

Stella S Yu

Peter Gerrard Ruminski

Leland J Chinn

Renee Huff

Paul Waddell Collins

Kerry W Fowler

Yi Yu

Hwang-Fun Lu

Kurt J Rorig

Richard John Lindmark

Konrad F Koehler

Suzanne E Radak

Srinivasan Raj Nagarajan

James W Malecha

Alan E Moormann

Mark Laurence Boys

Shashidhar N Rao

Lori A Schretzman

Albert Khilevich

John Adam Wendt

Yaping Wang

Mark A, Russell

Stella Siu-tzyy Yu

Nagarajan R Srinivasan

Yu Yi

Mihir D Parikh

The present invention relates to a class of compounds represented by the Formula Ior a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &#x3b1;&#x3b2;and/or &#x3b1;&#x3b2;integrin.

Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives

Pyrimidine compounds and derivatives thereof

Heterocyclic glycyl &bgr;-alanine derivatives

Gem-substituted &agr;v&bgr;3 antagonists

The present invention provides compounds of the formula Ar &mdash;Q&mdash;Ar &mdash;Y&mdash;R&mdash;Z and pharmaceutically acceptable salts thereof wherein Ar and Ar are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB production, such as psoriasis, ulcerative colitis, IBD and asthma.

LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use

The present invention relates to a class of compounds represented by the Formula I ##STR1## or a pharmaceutically acceptable salt thereof, wherein A is ##STR2## pharmaceutical compositions thereof and methods of using such compounds and compositions as .alpha..sub.v .beta..sub.3 antagonists.

Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid compounds

The present invention provides compounds of the formula Ar.sup.1 --Q--Ar.sup.2 --Y--R--Z and pharmaceutically acceptable salts thereof wherein Ar.sup.1 and Ar.sup.2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB.sub.4 production, such as psoriasis, ulcerative colitis, IBD and asthma.

LTA.sub.4 hydrolase inhibitors

LTA.sub.4 Hydrolase inhibitors

The present invention relates to compounds of the formula ##STR1## or a pharmaceutically acceptable salt thereof; wherein n is 0, 1 or 2;

Benzopyran class III antiarrhythmic agents

The invention relates to compound of the formula ##STR1## useful in regulating cardiac arrhythmias. This invention also relates to pharmaceutical compositions of the above-described compounds.

Substituted N-benzylpiperidine amides and cardiac regulatory

This invention encompasses compounds and methods for inhibiting lipoxygenase and includes a pharmaceutical composition comprising a pharmaceutical carrier and an effective lipoxygenase inhibiting amount of a compound of the formula: ##STR1## wherein the substituents are defined below. The compounds and pharmaceutical formulations of the present invention are 5-lipoxygenase inhibitors and, therefore, are useful in the treatment of local and systemic inflammation, allergy and hypersensitivity reactions and other disorders in which agents formed in the 5-lipoxygenase metabolic pathway are involved.

5-lipoxygenase inhibitors

Substituted N-benzylpiperidine amides, which have activity as Class III antiarrhythmic agents, acting by prolonging cardiac action potential repolarization. The invention further provides for compositions incorporating the compunds and methods of their use, as well as providing for pharmaceutically acceptable salts of the compounds.

Substituted N-benzylpiperidine amides

Compositions of matter are disclosed of compounds of the formula ##STR1## and the pharmaceutically acceptable acid addition salts thereof wherein X represents a halo, lower alkyl, hydrogen, trifluoromethyl, phenyl, or lower alkoxy substituent; Y represents --CN, --CONH.sub.2, --CON(R.sub.1).sub.2 or --CO.sub.2 R.sub.1 where R.sub.1 is a lower alkyl; m is the integer 1 or 2 and n is an integer from 1 to 3 inclusive; R.sub.2 represents lower alkyl; R.sub.3 represents lower alkyl or acetyl, aroyl, phenacetyl or trifluoroacetyl; A, B, and D are carbonyl or methylene such that when one of A, B, or D is carbonyl, the others are methylene and R.sub.3 is lower alkyl, whereas when R.sub.3 is acetyl, aroyl, phenacetyl or trifluoroacetyl, A, B, and D are methylene. These compounds have utility as antiarrhythmic agents.

Monobasic disobutamide derivatives

Growing community of inventors

Vernon Hills, IL, United States of America

Bipinchandra N Desai